Investor Relations
Investors
View the Latest Stock Trading Information
Review BioStem’s latest trading data, historical quotes, volume, and key statistics.
ALERTS
Sign Up For Email and Text Alerts
Get news, filings, and events directly in your inbox or phone with our automated Email Alerts.
Symbol
OTC: BSEMPrice
$Volume
Change
Delayed up to 15 minutes
Investor Relations
BioStem Technologies
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its portfolio of quality brands includes AmnioWrap2®, VENDAJE®, VENDAJE AC® and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
Press Releases
Latest News
March 30, 2026 07:00 am
BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025
March 24, 2026 04:05 pm
BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026 07:00 am
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
Quarterly
Results
Stock
Information
Presentations
& Brochures
Upcoming
Events